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Available online 3 November 2016A targeted customized sequencing of genes implicated in autosomal recessive polycystic kidney disease (ARPKD)
phenotype was performed to identify candidate variants using the Ion torrent PGM next-generation sequencing.
The results identiﬁed four potential pathogenic variants in PKHD1 gene [c.4870CNT, p.(Arg1624Trp), c.5725CNT,
p.(Arg1909Trp), c.1736CNT, p.(Thr579Met) and c.10628TNG, p.(Leu3543Trp)] among 12 out of 18 samples.
However, one variant c.4870CNT, p.(Arg1624Trp) was common among eight patients. Some patient samples
also showed few variants in autosomal dominant polycystic kidney disease (ADPKD) disease causing genes
PKD1 and PKD2 such as c.12433GNA, p.(Val4145Ile) and c.1445TNG, p.(Phe482Cys), respectively. All causative
variants were validated by capillary sequencing and conﬁrmed the presence of a novel homozygous variant
c.10628TNG, p.(Leu3543Trp) in a male proband.We have recently published the results of these studies (Edrees
et al., 2016). Here we report for the ﬁrst time the effect of the common mutation p.(Arg1624Trp) found in eight
samples on the protein structure and function due to the speciﬁc amino acid changes of PKHD1protein usingmo-
lecular dynamics simulations. The computational approaches provide tool predict the phenotypic effect of variant
on the structure and function of the altered protein. The structural analysis with the common mutation
p.(Arg1624Trp) in the native and mutant modeled protein were also studied for solvent accessibility, secondary
structure and stabilizing residues toﬁndout the stability of theprotein betweenwild type andmutant forms. Fur-
thermore, comparative genomics and evolutionary analyses of variants observed in PKHD1, PKD1, and PKD2
genes were also performed in some mammalian species including human to understand the complexity of ge-
nomes among closely related mammalian species. Taken together, the results revealed that the evolutionary
comparative analyses and characterization of PKHD1, PKD1, and PKD2 genes among various related and unrelated
mammalian specieswill provide important insights into their evolutionary process and understanding for further
disease characterization and management.
© 2016 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Polycystic kidney disease (PKD) is a clinically and genetically hetero-
geneous disorder with different modes of inheritance. There are two
fundamental types of hereditary polycystic kidney disorders, autosomal
dominant (ADPKD) and autosomal recessive (ARPKD). The ADPKD is
the most frequent and life-threatening genetic disease with a preva-
lence of one in 500–1000, affecting N12 million individuals worldwide.
The clinical symptoms usually not appear until adulthood; however,
about 2%–5% of patients with ADPKD show early clinical manifestations,-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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three types viz., PKD1 gene on chromosome 16, PKD2 gene on chromo-
some 4 and ADPKD 3 gene on an unknown chromosomal site, whereas,
the ARPKD gene is present on chromosome 6.
The ARPKD is considerably rare compared to its dominant counter-
part ADPKD with incidence rate of about one in 20,000 live births [1].
It could be diagnosed in utero or prenatally by sonography displaying
bilateral large echogenic kidneys and oligohydramnios in severe cases.
It has been reported thatmutations in the polycystic kidney and hepatic
disease 1 (PKHD1) gene are responsible for ARPKD and its severity de-
pends on the type of mutations [2].
The ADPKD is usually diagnosed through renal imaging using age-
related cyst quantity criteria; yet it is not effective to exclude disease
in vulnerable individuals under 40 years of age [3]. Themutation evalu-
ation of the ADPKD is hampered due to the large size multi-exons of
PKD1 and PKD2, occurrence of genomic duplication in PKD1,marked al-
lelic heterogeneity, and presence of common missense variations with
hypomorphic alleles [4]. About two-thirds of the PKD1 gene (exons 1–
33) is duplicated six times on chromosome 16 (pseudogenes PKD1P1-
P6) [5]. The PKD1 and PKD2 variation studies may provide prognostic
and diagnostic insights including pre-implantation hereditary diagnos-
tics for early-onset of ADPKD (Fig. 1A–B) [5].
The PKHD1 gene is located on the short arm of chromosome 6
(chr6p21) and encodes for ﬁbrocystin protein, which is present on the
primary cilium of the renal epithelial cells. There is a high risk of fetal
manifestation and neonatal death if the fetus has two truncating muta-
tions [6]. The PKHD1 gene is approximately 470 kb long encoding vari-
ous transcripts with sizes ranging from 9 to16 kb. The largest
uninterrupted open reading frame translates a denominated ﬁbrocystin
protein [7] or polyductin [7] of 447kD having 4074 amino residues. The
ﬁbrocystin/polyductin protein has a single transmembrane (TM)-
spanning domain near carboxyl end having six to seven TIG/IPT
(immunoglobin-like fold shared by plexins and transcription factors)
domains. Such structural motif with unidentiﬁed function has also
been recognized in a number of transmembrane receptors. Various
transcripts translate into truncated products lacking the TM and may
be secreted if translated [8]. The ﬁbrocystin is believed to be a trans-
membrane receptor/ligand that has a role in collecting duct and biliary
differentiation. Remarkably, in cultured renal epithelial cells theA B
C
Fig. 1. A) Normal health human adult kidney. B) Autosomal dominant polycystic kidney
disease: In adults, mutation of PKD1 gene (chromosome 16) that produces a
transmembrane protein polycystin1. Multiple, large, round cysts. Bilateral palpable
mass, ﬂank pain, hematuria, renal insufﬁciency. C) Autosomal recessive polycystic
kidney disease: In children condition of progressive & fatal renal failure. Multiple
enlarged cysts those are perpendicular to renal capsule and association with liver cysts
and bilateral palpable mass. Images were taken from a website (http://mynotes4usmle.
tumblr.com/post/41882865387/polycystic-kidney-disease).primary location of expression was found to be the primary cilium spe-
ciﬁcally the basal body of the cilium [9–10].
Characteristically, neonates have fusiform dilations of the collecting
ducts andhave portal and interlobularﬁbrosis of the liver alongwith the
biliary duct hyperplasia. Furthermore, respiratory failure, hypertension
and urinary tract infections are common occurrence. The disease typi-
cally clinically manifest either neonatal or in early childhood (Fig. 1C),
and about 30% of affected children die within the ﬁrst year of life [11].
However, appearance of ARPKD at later ages and survival into adult-
hood has been noticed in a considerable number of cases [12]. In these
cases, ARPKD can be clinically indistinguishable from autosomal domi-
nant polycystic kidney disease (ADPKD) [13]. The ARPKD gene,
denominated PKHD1 for polycystic kidney and hepatic disease, is situat-
ed on the short arm of chromosome 6 [14]. The disease is clinically het-
erogeneous nonetheless so far all families have been linked to this locus,
including patients with severe or with relativelymild progression of the
disease [15–16]. Nevertheless, congenital polycystic kidney disease can
be part of a number of syndromes, such as Meckel–Gruber Syndrome,
and Zellweger Syndrome [17].
Recently, we have validated the disease-causing variants due to
amino acid substitution [18] among ARPKD (PKHD1) and ADPKD
(PKD1 and PKD2) genes based on the exons and ﬂanking regions
study in Saudi patients using Ion-PGM sequencing. This study show
that based on the computational predictions an amino acid substitution
may eventually affect the protein function due to the structural alter-
ation causing stable changes in the involved domain. Results of this
study show that the ARPKD may be also caused as a result of partial or
complete loss of polyductin/ﬁbrocystin function. These methodological
strategies are useful tools before gene based and correlative analyses to
expand the understanding of ARPKD variant spectrum among Saudi
populations. The study also expounded on the challenges related to in-
terpretation of the pathogenicity of harmful variants in this large and
complex gene. Hence, a detailed study was conducted to investigate
the nucleotide sequences and their molecular organization of the
three genes among various mammalian species to understand the evo-
lution process of these genes.
2. Materials and methods
2.1. Ion torrent PGM next-generation sequencing (NGS)
Library construction, target enrichment, template preparation and
sequencing were performed as described in Edrees et al. [18]. In brief,
the DNA libraries and enrichment of targeted sequences of the genes
(PKHD1, PKD1 and PKD2) were achieved using Ion Plus Fragment Li-
brary kit, Ion Xpress bar-code adapters 1–16 kit and TargetSeq custom-
ized panel (Life Technologies). Template preparation and sequencing
were done using the Ion PGM Template Kit v2.0 and Ion PGM sequenc-
ing 200-kit v2 (Life Technologies) respectively. NGS data analysis was
performed using CLC Genomics Workbench v9, USA (http://www.
clcbio.com). The BAM binary format sequence data raw reads went
through adapter trimming, hence removal of reads shorter than 20 bp
and removal of exact duplicates, as well as quality trimming were per-
formed. The pre-processed reads were aligned with the reference ge-
nome (hg19) sequences corresponding to the customized genes. This
was followed by SNV and indel detection and all variants detectedwith-
in the exons of the customized genes were considered for subsequent
analyses using probabilistic variant detection method.
2.2. Multiple sequences alignment in phylogenetic analysis
DNA sequences for PKD1 and PKD2 and most of the PKHD1 proteins
analyzed were obtained by blastp or tblastn searches from the public
database NCBI (National Center for Biotechnology Information http://
blast.ncbi.nlm.nih.gov/Blast.cgi). The Protein sequence alignments
were performed using ClustalW (http://www.clustal.org/clustal2) and
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quence alignments were adjusted manually to maintain the alignment
of conserved domains and tominimize the number of gaps in the highly
variable loop regions. The phylogenetic model testing and Neighbor-
Joining calculations were performed using the program (http://
evolution.genetics.washington.edu/phylip/getme.html). The Neighbor-
joining tree of mammalian species was constructed using100 bootstrap
replicates. The pairwise distance matrix between DNA sequences was
constructed using the evolutionary model default parameter “JC69” in
Bioconductor program (https://www.bioconductor.org).
2.3. Solvent accessibility of amino acid residues
Amino acid solvent accessibility (ASA) was used that suggests sol-
vent accessibility of amino acid residues in proteins structures. The pro-
tein structure was retrieved from the Deﬁne Secondary Structure of
Proteins (DSSP) database of secondary structure assignments [19–20].
The DSSP software characterizes secondary structure, geometrical ap-
pearances and solvent structures of proteins in Protein data bank. The
software DSSP estimates entries from PDB (protein data bank) through
the entry implementation of ASA view for all the protein or individual
chain. The standard used was to add chain or PDB query in the input
ﬁle, exhibit ASA view plot for co-ordinate or PDB ﬁle. The amino acid
residues veriﬁed three forms of solvent accessibility i.e., buried, partially
buried and exposed indicating i.e., low, moderate and high accessibility
respectively [21]. The Secondary structurewas used for studying the as-
sociation between amino acid and protein structure.
2.4. Protein stability changes
Formanymutants (single amino acid changes or nsSNPs) in humans
and their impact on protein function remains unknown. Using compu-
tational approach provides binary classiﬁcations (impact/neutral)
along with a more rational score. Additionally, we get information
about the protein's stability through Schrodinger (BioLuminate, USA).
In themutated structure, the mutant residue was targeted in the native
protein structure. Many known disease-related nsSNPs in proteins with
identiﬁed 3D protein structure will have an effect on the structurally
signiﬁcant residues and sites signiﬁcant for the protein function. The
disease causing mutations typically occur in the protein residues that
are buried and at the hydrogen bonding residues [22]. In protein ki-
nases, comparisons show a cluster inside the functionally fundamental
catalytic core after residue scanning to repair the polar and neutral res-
idues in the protein stability analysis and solvent accessibility. In addi-
tion, it was also compared with the predictions of the functional effect
that were determined by the Screening for Non-Applicable Polymor-
phisms (SNAP) [23]. The SNAP scores range from−100 (strongly pre-
dicted as neutral) to 100 (strongly predicted to change function); the
gap is instantly related to the binary determination boundary (0),
which measures the reliability of the effect [24]. To demonstrate, dis-
ease-related mutationsmight possibly have an impact on protein inter-
actions [25]. The protein function is generally associated with the
evolutionarily conserved residues [26]. A damaging signal corresponds
to a mutation that is predicted to be stabilizing. The changes within
the folding free energy upon mutation (ΔΔG) support the idea that a
mutation may cause an alteration in the protein structure and function
eventually leading to disease. The SNAP score is related to additional
functional effects [27].
2.5. Molecular dynamics simulation
The structure of PKHD1 protein modeling was generated by iTasser
program [28]. The molecular dynamics (MD) simulation programs
used were CHARMM++ [29] and Gromacs [30]. The simulation to ob-
tain the solvated process was neither minimized nor equilibrated, nev-
ertheless 0.15 M ions were added within the simulation box byspecifying ions (KCl) and concentration (C). The ions had been sponta-
neously established by means of the ion-accessible volume (V), whole
charge of the conduct (Qsys), and by means of the conﬁdent ion (z+)
valency to neutralize the whole system charge, (z+N+−N− = −
Qsys). The ion-available volume (V) used to be anticipated with pro-
mote of subtracting molecular volume from the entire system and de-
termining the ion-placing method of Monte Carlo (MC). The solvation
free energy was once expressed as nonpolar and electrostatic contribu-
tions, but the nonpolar contribution was again partitioned into repul-
sive and dispersive contributions utilizing the weeks. The preface
conﬁguration of ions conﬁrmed the short MC simulations with a primi-
tive model equivalent to Van der Waals (VdW) interactions. The free
energy simulations had been carried out with few speciﬁc solvent
water molecules in close proximity to the solute, even as the inﬂuence
of the intermission of the solvent mass used to be proven implicitly as
an effective solvent boundary potential (SSBP). The KCl used to be in-
cluded in the box to neutralize the overall poor charge of the PKHD1
protein model. MD simulations had been conduct out with a 2 fs time
step at a consistent temperature of 300 K and a constant pressure of
1 atm below periodic solvent boundary stipulations. The Particle Mesh
Ewald (PME) approach was utilized for electrostatics, and a 12 Å cutoff
was once utilized for VdW interactions. The TIP3P water model was
used to model the solvent [31].
3. Results
3.1. High-throughput sequencing, mapping and coverage
To discover DNA variants of disease causing genes involved in genet-
ic disorders, we designed a unique high throughput density capture
array 538,751 targeted coverage exons sequences of 20 genes including
three genes (PKHD1, PKD1 and PKD2) causing polycystic kidney disease.
A total of 18 patient's sampleswere analyzed. The functional variant de-
tection was performed using targeted customized genes, where a total
of 543,366 (P16)–2,444,050 (P10) high-quality map reads were obtain-
ed, encompassing 2,009,135 (P6)–2,444,050 (P10) high-quality bases
per patient. Following mapping with the reference human genome,
about 90% yielded clean reads uniquely coordinated to the target re-
gions and about 98% of the targeted region covered with at least 95%
foldsmeandepth coverage for each sample. The average depth coverage
for exons among the 12 patient samples was 98% with highest depth
coverage of 99%, adequate to reliably detect DNA variants within the
majority of the targeted regions.
3.2. Functional regions are conserved in different species
The sequence similarity based on conserved regions in a region pro-
vides valuable information, therefore the human PKHD1, PKD1, PKD2
genes conserved regionswith signiﬁcant orthologous among other spe-
cies using NCBI-BLAST were examined. We found that in 71 out of 76
(93%) showed conserved regions and 167 out of 270 (61%) showed
human query sequences that were experimentally veriﬁed to be func-
tional. It is most likely that all conserved regions matching the domain
in a particular region, therefore NCBI-BLAST may exclude many other
domains by considering conserved segments individually. The identi-
ﬁed conserved domains in a region indicated new or same function of
the conserved regions in three genes targeted. The SMART BLAST was
used to identify some homologous regions for these human functional
regions. Discontinuous SMART BLAST has been able to identifymore di-
vergent sequence similarity than NCBI-BLAST. Using a recommended
parameter combination (-A 50 -t 21 -W 11 -N 1), we identiﬁed hits in
80 out of 156 clustered conserved domain regions. Among them, only
76 of clustered conserved region domains have NCBI-Blast hits with
an E-value less than 1E-10. In all these regions, our method identiﬁed
all NCBI-BLAST hits as conserved segments. Among 71 out of the 76
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gions, the results identiﬁed more conserved segments than Smart Blast.
3.3. Phylogenetic orthologs of genomic conserved regions
The single nucleotide variation (SNV) position affected targets in
three genes i.e., PKHD1, PKD1, and PKD2were studied and used for phy-
logenetic analysis. The results obtained by using the two different
methods [(CLCbio and PhyML (http://atgc.lirmm.fr/phyml)] were al-
most identical, in addition to their corresponding internal bootstrap
support, demonstrating the reliability of the phylogenetic analysis. The
phylogenetic tree showed Homo sapiens (human), Pan troglodytes
(chimpanzee), and Gorilla within one group and showed a clustering
topology in general well supportedwith high bootstrap values. The per-
centage of coding nucleotides in the PKHD1 gene varied across taxawithFig. 2. Phylogenetic analysis of PKHD1 ClustalWMultiple sequence alignment of the conserved
and p.(Leu3543Trp) in different mammalian species out of 100 orthologs vertebrate sequences
p.(Arg1624Trp) among 9 species, p.(Arg1909Trp) among 14 species, and p.(Leu3543Trp) among
the donor-related conserved amino acids in the human PKHD1 are illustrated in the red. For ea
conserved related amino acid positions are shownwithin each domain as clear highlight letters
from various mammals. B). The tree is based on a ClustalW using Neighbor joining algorithm
shown at each branch point (100 replicates) among the orthologs of PKHD1.the highest detected in Chlorocebus sabaeus (green monkey), Macaca
mulatta (rhesus macaque), Macaca nemestrina (pig tailed macaque),
and Mandrillus leucophaeus (drill) (100%) in one taxon and lowest in
Pan paniscus (bonobo) (79%). This validated the fact that the coding
region of PKHD1 gene in variants (c.4870CNT, p.(Arg1624Trp),
c.5725CNT, p.(Arg1909Trp), c.1736CNT, p.(Thr579Met) and
c.10628TNG, p.(Leu3543Trp) position were absolutely conserved (Fig.
2A and B). To view and understand the phylogenetic inter-relationship
among all the 14 mammalian species at genetic level, an un-rooted
Neighbor-joining (NJ) tree was constructed. As expected, all mammal
species fell in one group and rodents in another. Homo sapiens
(human) and Pan troglodytes (chimpanzee) were closer (100%) to
each other. Moreover, Camelus dromedarius (arabian camel), and Bos
taurus (cattle), belonged to one clade, Canis lupus familiaris (dog) and
Felis catus (cat) belonged to another clade with Chinchilla lanigeraPKHD1 domains in targeted amino acids p.(Thr579Met), p.(Arg1624Trp), p.(Arg1909Trp)
analyzed. A). The relative positions of p.(Thr579Met) among 14 highly conserved species,
13 species are illustrated and highlighted for each conserved amino acids. The positions of
ch positions if conserved at N99%, are shown with a different color residue, and the highly
on a solid background. Unrooted phylogenetic treewas included all known PKHD1 protein
alignment of the amino-acid sequences. The distance scale and bootstrapping values are
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pectedly, Canis lupus familiaris (dog) and Felis catus (cat) belonging to
the super order placental mammals, to which Bos taurus (cattle) and
Camelus dromedarius (arabian camel) also belong fell separately to
clade superorder and placental mammals super order organisms.
Being the out-groups, Chinchilla lanigera (long tailed chinchilla) and
Rhinopithecus roxellana (golden snub nosed monkey) were in separate
groups. Interestingly,Homo sapiens (human) and Pan troglodytes (chim-
panzee) were in the same group and matched for all the studied genes
however, PKD1 gene did not match with any regions and aligned with
the Homo sapiens (human). Even though the original Homo sapiens
(human) gene nucleotide as well as protein sequences matched with
all the mammalian species that were included for the phylogeny tree
construction, it was apparent that all altered variant forms of three
genes PKHD1, PKD1 and PKD2 in Saimiri boliviensis (black capped squir-
rel monkey) and Callithirix jacchus (common marmoset) formed a sep-
arate clade, but in reality all three genes and protein in Homo sapiens
(human) showed similarity with Chlorocebus sabaeus (green monkey),
Macaca mulatta (rhesus macaque), Macaca nemestrina (pig tailed ma-
caque), and Mandrillus leucophaeus (drill). This result also signiﬁes
that Homo sapiens and Pan troglodytes showed similarity to each other
for PKD1 and PKD2 genes. It was already known that functionally both
these mammalian species are closer to each other than to any other
Hominoidea, hence sequence similarities in both these taxa at the
gene and protein level is no surprise. It has already been reported that
the PKD1 and PKHD1 of Placental mammalian organisms exhibits a pro-
pensity for recombinational exchange with the closely linked genes.
Hence, apart from characterization at the gene level, we also have
taken into consideration the protein sequences in all the 12mammalianFig. 3. Phylogenetic analysis of PKD1 ClustalWMultiple sequence alignment of the conserved PK
vertebrate sequences analyzed. A) The relative position of p.(Val4145Ile) among 11 highly co
positions of the donor-related conserved amino acids in the human PKD1 are illustrated in th
amino acid, and the highly conserved related positions within each domain are shown as cle
PKD1 various among mammals. B) The tree was based on ClustalW analysis using Neighbor
values are shown at each branch point (100 replicates), among the orthologs of PKD1.species including Equus caballus (alpaca) and Equus caballus (horse) to
ascertain the functional level changes across the species. Results of the
PKD1 protein alignment p.(Phe482Cys) in all 12 species were found to
be remarkably similar with Homo sapiens (human) and Pan troglodytes
(chimpanzee) (Fig. 3A and B). The Papio anubis (olive baboon) se-
quences were found to be similar to only one substitution at codon po-
sition 482, signifying that plenty of conservation exists at the PKD1
protein level in closely relatedmammalian species, unlike at the genetic
level, we did not ﬁnd “Phe” or the “Cys” amino acid position inHomo sa-
piens (human) PKD1protein sequence. Instead, Phewas observed at the
different codon position. Similar to human PKD1 protein, Phe was also
detected at the same position for Pan troglodytes (chimpanzee, Papio
Anubis (olive baboon), and Macaca fascicularis (crab eating macaque).
Absolute protein homologywas observedwith the rodent species. How-
ever, interestingly chimpanzee showedmissing codons in PKD2 (Fig. 4A
and B). To further assess the evolutionary relationship among all the 14
mammalian species, an Unrooted phylogenetic tree was also construct-
ed based on the protein sequences and inferences were drawn.
3.4. Protein stability changes
To realize the thermodynamic protein stability alterations as a con-
sequence of the p.(Arg1624Trp) common mutation in protein,
PopMuSic-2.0 [32] and Schrodinger-BioLuminate (http://www.
Schrodinger.Com/BioLuminate/) was utilized based on the statistical
potentials of narrow sequence coefﬁcients to check the solvent accessi-
bility model after the mutation. This algorithm conﬁrmed that the
amino acid change from “Arg” to “Trp” at position 1624 would affect
the protein function due to the excessive free energy (ΔΔG = 0.64D1domains in targeted amino acid p.(Val4145Ile) in different species out of 100 orthologs
nserved species are shown in the highlighted rows of each conserved amino acids. The
e red. For each positions if conserved at N98% are shown with a different color for each
ar highlight letters on a solid background. Unrooted phylogenetic tree for all of known
-joining alignment of the amino-acid sequences. The distance scale and bootstrapping
Fig. 4. Phylogenetic analysis of PKD2 ClustalWMultiple sequence alignment of the conserved PKD2 domains for targeted variant amino acid p.(Phe482Cys) in different species out of 100
orthologs vertebrate sequences analyzed. A) The relative position of p.(Phe482Cys) among 12highly conserved species is shown. The positions of the donor-related conserved amino acids
in the human PKD2 are illustrated in the red. For each position if conserved at N99% are shownwith a different color residue, and the highly conserved related amino acid positionswithin
each domain are shown as clear highlight letters on a solid background. Unrooted phylogenetic tree for all of known PKD2 various among mammals. B) The tree was derived from a
ClustalW analysis based on Neighbor joining alignment of the amino-acid sequences. The distance scale and bootstrapping values are shown at each branch point (100 replicates),
among the orthologs of PKD2.
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pared to the wild type (ΔΔG = 0.01 kcal/mol). The novel mutation
caused a signiﬁcant (r2 = 0.8) distortion in the protein folding particu-
larly in the region of mutation and caused stability changes. The solvent
accessibility (Acc) modeling alter the protein structure, indicating that
the Acc for mutant p.(Arg1624) was 39.01 (31%) compared to 30.82
(30%) for the wild type structure p.(1624Trp). The structural weak
spot used to be radically better than the usual, specify how a mutant
site may alter the proper function of a protein when it is un-stabilize.
3.5. Molecular dynamics and simulation of common variant
The program of iTasser PKHD1 protein structure modeling and pre-
dicted binding site amino acid residues were 144, 174, 175, ref; com-
mon mutation p.(Arg1624Trp), which is highly binding with peptide
reference based on this protein PDB ID: 1TDQ. The CscoreLB is the con-
ﬁdence score of predicted binding site and its value range between 0
and 1. The predicted protein score was 0.01; a higher score indicates a
more reliable ligand-binding site prediction. The BS-score was 0.13, a
measure of local similarity (sequence & structure) between template
binding site and predicted binding site in our targeted protein structure.
Based on large scale benchmarking analysis, we have observed that a
BS-score N 1 reﬂects a signiﬁcant local match between the predicted
and template binding site. The TM-score was 0.459, a measure of global
structural similarity between targeted region and template protein. The
RMSDwas 4.38 between residues that were structurally aligned by TM-
align. The IDENa 0.045 is the percentage sequence identity in the struc-
turally aligned region. The coverage was 0.628 representing the cover-
age of global structural alignment and was equal to the number of
structurally aligned residues divided by length of the targeted protein
structure regions. The corresponding position was performed utilizing
SWISS-PORT considered separately to receive altered protein model
structures. The energy minimizations accomplished by YASARA and
NOMAD-Ref Gromacs using force ﬁeld energy for the native typeprotein PKHD1 protein structure and mutant type protein structure
based on the proteinmodel RMSD. The complete energy of native struc-
ture of PKHD1 and mutant model structure residue of common muta-
tion (Arg1624Trp) have been calculated and showed 0.25 to 0.50
RMSD variation between the wild and mutant protein structures (Sup-
plementary Fig.1). The entire energy for the native PKHD1 protein
structure after energy minimization was −244,080.5 kJ/mol with a
0.52 score, compared to before energy minimization structure which
was 207,844,375.1 kJ/mol with−3.14 score. The CHARMM graphical
interface (GUI) for MD simulations revealed the consequence of the
p.(Arg1624Trp) mutation under speciﬁc solvent conditions, by
performingmolecular dynamics and stability investigations for the pre-
dicted PKHD1 protein and compared it with the native structure. The
solvate was used to create a realistic aqueous solvent environment
around the protein model PKHD1 with water. The solvate determines
the dimension of process with octahedral shapes of water box ﬁtting
to fully solvate the molecule with side distance 10.0.
4. Discussion
Wehave recently published and validated the disease-causing novel
variants as a result of amino acid alteration amongARPKD (PKHD1) and
ADPKD (PKD1 and PKD2) genes based on the exons and ﬂanking re-
gions analysis in Saudi patients using Ion-PGM sequencing [18]. In this
study based on the computational predictions we conﬁrmed that the
amino acid substitution eventually affects the protein function due to
the structural alteration resulting in the stable changes in the protein
structure.
Polycystic kidney disease (PKD) is a common genetic disease charac-
terized by the accumulation of multiple ﬂuid-ﬁlled cysts in each kidney
and other organs. The renal cysts from the renal tubular epithelial cells
lined by way of a single layer of cells that have better rates of cellular
proliferation and apoptosis, and are much less differentiated than the
normal tubular cells. Progression of cysts in the kidneys ultimately
133B.M. Edrees et al. / Genomics Data 10 (2016) 127–134causes end-stage renal disease (ESRD), which makes PKD one of the
leading causes of ESRD in children and adults [33]. Pooling and bar cod-
ing process to reap price-affectivity so that NGSwould be utilized to an-
alyze large ADPKD and ARPKD genes. The ﬁndings of this study indicate
that the ARPKDmay be also caused as a result of partial or complete loss
of polyductin/ﬁbrocystin function.
Although still very high, the cost of NGS is gradually decreasing due
to novel strategies for library preparation, decreased hardware cost, and
greater sequence output per run [34]. Ion-torrent probably makes NGS
an attractive approach additionally for clinical and diagnostic applica-
tion, chieﬂy when simplest particular genes or speciﬁc sets of genes
through to be analyzed, such as we investigated for ADPKD and
ARPKD genes [18].
In an effort to maximize the accuracy of our pathogenicity estimates
for themissense variants, we combined various computationalmethods
to predict its effects on the protein stability due to disease-causingmis-
sense mutations as it has been reported that the function of a protein
can be affected in a variety of ways [35]. Among them, the most com-
mon effect is changing protein stability, i.e. destabilizing or stabilizing
the wild type protein fold [36–37]. The validation of the identiﬁed vari-
ants in our previous study [18] due to amino acid substitution and its
impact of the protein structure and function due to the stability changes
were studied using computational simulation techniques. The six iden-
tiﬁed variants displaying clinical signiﬁcancewere studied further using
computational methods and showed that the predicted protein with
mutant variant structure will have inﬂuence on the protein function.
However, the predictions about the changes of the folding energy not
only indicate whether they favor the stability or not, but the predicted
absolute magnitude should be accurate as well to allow to distinguish
between disease-causing and harmless mutations. Because of this sig-
niﬁcant effort were devoted to develop methods and approaches to
evaluate the stability changes upon amino acid substitutions, but de-
spite of the efforts, accurate calculations of folding free energy are still
a challenge [38].
The study also investigated the integrative and cross-species com-
parative genomics analysis among theAPRKDandADPKDgenes. The re-
sults showed that the APRKD and ADPKD genes were evolutionarily
conserved across different mammalian species apart from the genomic
alterations. It has been shown that the human genes PKHD1, PKD1 and
PKD2 are highly conserved in the mouse and suggested that the intri-
cate splicing pattern is likely to be functionally important [39]. Further-
more, the larger the evolutionary distance between the aligned different
species, the lower the risk of over predicting pathogenicity. The study
was based on the alignment ranging from tolerance to variation for
the amino acid position in question by aligning the homologues of the
protein from various species, and compares the tolerance to themagni-
tude of the chemical alteration caused as a result of particular variant.
The three genes PKHD1, PKD1 and PKD2 alignment of protein and
amino acid sequences when compared with 14 mammalian species in-
cluding Pan troglodytes (chimpanzee). The observation that the human
and mouse genes shared complex patterns of splicing prompted us to
examine whether speciﬁc features were conserved. We compared the
speciﬁc patterns of splicing, the relative position and sequence of
exons that occasionally used alternative splice sites, and the relative po-
sition and sequence of unique exons that were not part of the 67 exon
longest ORF transcript. These three genes are thought to give rise,
through alternative splicing, to thousands of isoforms. Interestingly,
the pattern of alternative exon and splice-site usage is very similar to
what we have observed for human and mouse Pkhd1. In the case of
neurexins, alternative splicing has been shown to result in products
with different ligand binding properties [40–41].
The MD simulation under solvated conditions were also integrated
to the predicted protein domain structure based on the amino acid se-
quences of PKHD1 gene. The predicted protein domain macromolecular
structure was constructed using Charm++ and Gromacs compu-
tational programs and was studied for the stability and structuralconsequences compared to the mutant structure. The computational
analysis is not aimed at predicting the absolute value of the expected
energy changes, but rather to predict whether it is stabilizing or
destabilizing and more importantly to reveal the details of the sug-
gested changes. The foremost advantage of the structure-based ap-
proaches is that they could illustrate the details of the changes causing
the malfunction in a corresponding protein and in principle these ﬁnd-
ings could be used to develop therapeutics to neutralize the ill effects as
result of such alterations. In the future, it may be feasible to analyze nat-
urally occurring variations in the genome sequence, predict the bio-
physical effect of the mutation, and estimate the likelihood of a given
variation to be tolerating or damaging. Such studies could also suggest
further research strategies into protein function, and possibly, muta-
tion-speciﬁc therapies. Although, many of these proteins are experi-
mentally intractable, the strategy presented here could make not only
mutation studies in several human proteins possible for further analyz-
ing thembut also for designing efﬁcient diseasemanagement strategies.5. Conclusion
The study demonstrated on the challenges related to interpretation
of the pathogenicity of harmful variants in large and complex genes
such as causing ARPKD. Hence, a detailed studywas conducted to inves-
tigate the nucleotide sequences and their molecular organization of the
three genes among various mammalian species to understand the evo-
lution process of these genes. The study validated the disease-causing
common variant p.(Arg1624Trp), whichwas highly associated with au-
tosomal recessive polycystic kidney disease (ARPKD) using Ion-PGM se-
quencing. Overall, the results were discussed with an inference on the
role of evolutionary forces in maintaining such close comparisons and
variations across closely related taxa. Further studies are needed to uti-
lize more comparative approaches to understand the disease causing
genes evolution in closely related mammalian species. These methodo-
logical strategies are useful tools before gene based and correlative anal-
yses to expand the understanding of ARPKD variant spectrum among
Saudi populations.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.gdata.2016.10.009.Author contributions
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